-+ 0.00%
-+ 0.00%
-+ 0.00%

Alebund Pharmaceuticals, R1 Therapeutics partner on global development of AP306 outside Greater China

PUBT·07/21/2026 11:01:48
Listen to the news
Alebund Pharmaceuticals, R1 Therapeutics partner on global development of AP306 outside Greater China
  • Alebund Pharmaceuticals granted R1 Therapeutics an exclusive license for AP306 outside mainland China, Hong Kong, Macau, Taiwan under a December 2025 deal.
  • The partners co-sponsor a global Phase IIb trial in hyperphosphatemia patients on maintenance hemodialysis, with sites in the US and China.
  • Alebund retained full rights in its four home markets; each party will handle trial execution and regulatory filings in its own territory.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alebund Pharmaceuticals (Jiangsu) Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN08843) on July 21, 2026, and is solely responsible for the information contained therein.